

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UN-AUDITED)
AS AT AND FOR THE PERIOD ENDED 31 MARCH 2026
(Third Quarter)

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Condensed Consolidated Statement of Financial Position (Un-Audited)
As at 31 March 2026

Particulars	Notes	Amount In BDT	
		31-Mar-26	30-Jun-25
Assets			
Non-Current Assets		39,648,742,912	38,259,044,041
Property, Plant and Equipment	6	20,254,235,618	20,646,613,960
Right of use Assets	7	43,261,575	43,843,671
Capital Work in Progress	8	11,949,960,005	10,246,869,406
Investment in Associates	10	1,468,102,000	1,389,691,000
Other Investments	11	5,933,183,715	5,932,026,004
Current Assets		17,494,994,400	17,537,104,439
Inventories	12	1,077,453,790	1,505,203,198
Trade and Other Receivables	13	15,345,449,685	15,045,994,727
Advances, Deposits & Prepayments	14	923,754,294	859,623,154
Fixed Deposit with Banks	15	66,489,996	54,182,849
Cash and Cash Equivalents	16	81,846,635	72,100,511
Total Assets		57,143,737,312	55,796,148,480
Shareholders' Equity and Liabilities			
Shareholders' Equity		19,997,949,177	20,145,835,747
Share Capital	17	2,340,000,000	2,340,000,000
Share Premium		8,016,892,026	8,016,892,026
Reserves	18	3,002,499,547	2,931,626,290
Retained Earnings	19	6,638,557,605	6,857,317,431
Non - Controlling Interest	20	1,433,765,025	1,472,257,451
Total Equity		21,431,714,202	21,618,093,198
Non-Current Liabilities		27,212,158,363	25,713,831,431
Provision for Decommissioning of Assets		143,405,563	143,405,563
Long Term Loan	21	26,583,332,962	25,136,615,253
Lease Obligation	22	32,160,559	31,688,563
Deferred Tax Liability	23	453,259,279	402,122,053
Current Liabilities		8,499,864,747	8,464,223,850
Current Portion of Lease Obligation	22.1	14,019,887	14,932,954
Short term loans	24	409,585,325	493,700,373
Trade and Other Payables	25	7,160,574,173	7,068,074,231
Employee Benefits	26	98,809,311	102,751,749
Unclaimed/Unpaid Dividend		284,422,939	284,463,833
Accrued Expenses	27	532,453,112	500,300,711
Total Equity & Liabilities		57,143,737,312	55,796,148,480
Number of Shares Used to Compute NAV		234,000,000	234,000,000
Net Asset Value (NAV) Including Revaluation Surplus	33	85.46	86.09
Net Asset Value (NAV) Excluding Revaluation Surplus		77.72	78.34

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

Sd/-
Director
2

Sd/-
Managing Director

Sd/-
Chairman

ORION PHARMA LIMITED
Condensed Statement of Financial Position (Un-Audited)
As at 31 March 2026

Particulars	Notes	Amount In BDT	
		31-Mar-26	30-Jun-25
Assets			
Non-Current Assets		31,117,084,312	29,718,361,249
Property, Plant and Equipment	6a	14,505,577,017	14,888,931,168
Right of use Assets	7	43,261,575	43,843,671
Capital Work in Progress	8	11,949,960,005	10,246,869,406
Investment in Subsidiaries	9	1,017,000,000	1,017,000,000
Investment in Associate	10	1,468,102,000	1,389,691,000
Other Investments	11a	2,133,183,715	2,132,026,004
Current Assets		11,023,823,402	11,020,877,847
Inventories	12a	514,406,501	578,614,007
Trade and Other Receivables	13a	9,536,031,300	9,560,830,623
Advances, Deposits & Prepayments	14a	841,467,377	776,530,869
Fixed Deposit with Banks	15	66,489,996	54,182,849
Cash and Cash Equivalents	16a	65,428,228	50,719,499
Total Assets		42,140,907,715	40,739,239,096
Shareholders' Equity and Liabilities			
Shareholders' Equity		13,453,359,173	13,470,447,872
Share Capital	17	2,340,000,000	2,340,000,000
Share Premium		8,016,892,026	8,016,892,026
Reserves	18a	2,654,953,890	2,583,749,253
Retained Earnings	19a	441,513,257	529,806,593
Non-current Liabilities		27,068,752,800	25,570,425,868
Long term loan	21a	26,583,332,962	25,136,615,253
Lease obligation	22	32,160,559	31,688,563
Deferred tax liability	23	453,259,279	402,122,053
Current Liabilities		1,618,795,741	1,698,365,355
Current portion of finance lease obligation	22.1	14,019,887	14,932,954
Short term loans	24	409,585,325	493,700,373
Trade and other payables	25a	454,336,451	463,865,669
Employee benefits	26a	11,310,372	11,310,372
Unclaimed/Unpaid Dividend		284,422,939	284,463,833
Accrued expenses	27a	445,120,768	430,092,154
Total Equity & Liabilities		42,140,907,715	40,739,239,096
Number of Shares Used to Compute NAV		234,000,000	234,000,000
Net Asset Value (NAV) Including Revaluation Surplus	33a	57.49	57.57
Net Asset Value (NAV) Excluding Revaluation Surplus		51.74	51.80

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

Sd/-
Director

Sd/-
Managing Director

Sd/-
Chairman

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (Un-Audited)
For The Period Ended 31 March 2026

Particulars	Notes	Amount In BDT			
		July 2025 to March 2026	July 2024 to March 2025	January to March 2026	January to March 2025
Revenue from Net Sales	28	2,281,280,618	3,352,010,387	1,486,758,905	845,073,515
Cost of Goods Sold		(1,212,468,880)	(1,213,812,662)	(788,950,187)	(388,580,852)
Cost of Power Generation		(108,776,274)	(892,898,341)	(72,061,362)	(40,863,656)
Gross Profit		960,035,464	1,245,299,383	625,747,355	415,629,007
Operating Expenses		(950,156,741)	(1,036,083,546)	(631,604,328)	(343,442,180)
General & Administrative Expenses		(350,672,911)	(361,583,235)	(236,979,225)	(101,645,804)
Selling & Distribution Expenses		(599,483,830)	(674,500,311)	(394,625,104)	(241,796,376)
Profit from Operation		9,878,723	209,215,837	(5,856,973)	72,186,827
Financial Expenses	29	(216,354,810)	(235,507,570)	(133,093,261)	(59,865,499)
Non Operating Income/ (Loss)	30	5,385,607	16,015,459	3,915,501	7,718,405
Net Profit from Operation		(201,090,480)	(10,276,274)	(135,034,734)	20,039,734
Workers Profit Participation Fund		-	(8,569,375)	-	(3,455,784)
Net Profit before Tax		(201,090,480)	(18,845,649)	(135,034,734)	16,583,950
Income Tax		(65,086,933)	(80,640,364)	(43,687,349)	(25,681,239)
Current Tax (Expenses)/Income	31	(13,720,001)	(15,302,738)	(8,944,050)	(5,088,665)
Deferred Tax (Expenses)/Income	31	(51,366,932)	(65,337,625)	(34,743,299)	(20,592,574)
Net Profit after Tax		(266,177,412)	(99,486,012)	(178,722,083)	(9,097,289)
Share of Profit from Associate		6,290,600	6,202,000	3,765,500	1,639,100
Net Profit		(259,886,812)	(93,284,012)	(174,956,582)	(7,458,189)
Less: Non Controlling Interest (share of operating profit)		38,492,426	51,912,402	23,279,285	13,282,310
Net Profit after Tax before Other Comprehensive Incon		(221,394,386)	(41,371,610)	(151,677,298)	5,824,121
Other Comprehensive Income		73,507,217	(396,215,408)	(878,671,208)	(155,839,056)
Fair Value Gain of Marketable Securities		1,157,111	(2,865,470)	(726,629)	709,809
Fair Value Gain on Investment in Associate		72,175,686	(394,584,467)	(878,076,801)	(156,834,303)
Share of Other Comprehensive Income		(55,286)	314,467	(170,699)	145,203
Deferrred tax Income (Expenses) on Revaluation Surplus of PPE & Fair Value Changes of Marketable securities		229,706	920,062	302,921	140,236
Total Comprehensive Income Attributable to Ordinary Shareholders		(147,887,169)	(437,587,018)	(1,030,348,506)	(150,014,935)
Number of Shares Used to Compute EPS		234,000,000	234,000,000	234,000,000	234,000,000
Earnings Per Share (EPS)	32	(0.95)	(0.18)	(0.65)	0.02

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

Sd/-
Director

Sd/-
Managing Director

Sd/-
Chairman

ORION PHARMA LIMITED

Condensed Statement of Profit or Loss and Other Comprehensive Income (Un-Audited)

For The Period Ended 31 March 2026

Particulars	Notes	Amount In BDT			
		July 2025 to March 2026	July 2024 to March 2025	January to March 2026	January to March 2025
Revenue from Net Sales	28.a	2,281,280,618	2,534,439,608	738,605,365	845,073,515
Cost of Goods Sold		(1,212,468,880)	(1,213,812,662)	(400,271,842)	(388,580,852)
Gross Profit		1,068,811,738	1,320,626,945	338,333,523	456,492,663
Operating Expenses		(907,942,336)	(996,953,844)	(296,962,831)	(332,251,409)
General & Administrative Expenses		(308,458,507)	(322,453,533)	(95,240,928)	(90,455,033)
Selling & Distribution Expenses		(599,483,830)	(674,500,311)	(201,721,904)	(241,796,376)
Profit from Operation		160,869,401	323,673,101	41,370,691	124,241,255
Financial Expenses	29.a	(198,055,191)	(159,731,686)	(945,619)	(59,388,194)
Non Operating Income/ (Loss)	30.a	5,385,607	16,015,459	1,307,876	7,718,405
Net Profit from Operation		(31,800,182)	179,956,874	41,732,948	72,571,466
Workers Profit Participation Fund		-	(8,569,375)	-	(3,455,784)
Net Profit before Tax		(31,800,182)	171,387,499	41,732,948	69,115,682
Income Tax		(65,086,933)	(80,640,364)	(23,000,163)	(25,681,239)
Current Tax (Expenses)/Income	31	(13,720,001)	(15,302,738)	(4,439,479)	(5,088,665)
Deferred Tax (Expenses)/Income	31	(51,366,932)	(65,337,625)	(18,560,684)	(20,592,574)
Net Profit after Tax		(96,887,116)	90,747,135	18,732,785	43,434,443
Share of Profit from Associates		6,290,600	6,202,000	1,196,100	1,639,100
Net Profit after Tax before Other Comprehensive Income		(90,596,516)	96,949,135	19,928,885	45,073,543
Other Comprehensive Income		73,507,217	(396,215,408)	(45,477,097)	(155,839,056)
Fair Value Gain of Marketable Securities		1,157,111	(2,865,470)	1,369,827	709,809
Fair Value Gain on Investment in Associate		72,175,686	(394,584,467)	(47,000,532)	(156,834,303)
Share of Other Comprehensive Income		(55,286)	314,467	175,432	145,203
Deferred tax Income (Expenses) on Revaluation Surplus of PPE & Fair Value Changes of Marketable securities		229,706	920,062	(21,824)	140,236
Total Comprehensive Income attribute to Ordinary Shareholders		(17,089,299)	(299,266,273)	(25,548,212)	(110,765,512)
Number of Shares Used to Compute EPS		234,000,000	234,000,000	234,000,000	234,000,000
Earnings Per Share (EPS)	32.a	(0.39)	0.41	0.09	0.19

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

Sd/-
Director

Sd/-
Managing Director

Sd/-
Chairman

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Condensed Consolidated Statement of Changes in Equity (Un-Audited)
For The Period Ended 31 March 2026

Amount in BDT

Particulars	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total	Non controlling Interest	Total
Balance at 01 July 2025	2,340,000,000	8,016,892,026	2,931,626,290	6,857,317,431	20,145,835,747	1,472,257,451	21,618,093,198
Net Profit after Tax	-	-	-	(221,394,386)	(221,394,386)	(38,492,426)	(259,886,812)
Fair Value Gain /(Loss) on Investment in Associate			72,175,686	-	72,175,686	-	72,175,686
Fair Value (Loss)/Gain on Marketable Securities			1,157,110	-	1,157,110	-	1,157,110
Adjustment for sale of Mkt. Securities			600	-	600	-	600
Share of Other Comprehensive Income			(55,286)	-	(55,286)	-	(55,286)
Adjustment of Deferred tax on Revaluation Surplus			229,706	-	229,706	-	229,706
Depreciation on Revaluation Surplus			(2,634,560)	2,634,560	-	-	-
Balance at 31 March 2026	2,340,000,000	8,016,892,026	3,002,499,547	6,638,557,605	19,997,949,177	1,433,765,025	21,431,714,202

For The Period Ended 31 March 2025

Amount in BDT

Particulars	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total	Non controlling Interest	Total
Balance at 01 July 2024	2,340,000,000	8,016,892,026	3,683,345,150	7,499,339,162	21,539,576,338	1,543,272,725	23,082,849,063
Net Profit after Tax	-	-	-	(41,371,610)	(41,371,610)	(51,912,402)	(93,284,012)
Cash Dividend for the year 2023-2024				(234,000,000)	(234,000,000)	-	(234,000,000)
Fair Value Gain /(Loss) on Investment in Associate			(394,584,467)	-	(394,584,467)	-	(394,584,467)
Fair Value (Loss)/Gain on Marketable Securities			(2,865,470)	-	(2,865,470)	-	(2,865,470)
Adjustment for sale of Mkt. Securities			1,350	-	1,350	-	1,350
Share of Other Comprehensive Income			314,467	-	314,467	-	314,467
Adjustment of Deferred tax on Revaluation Surplus			920,062	-	920,062	-	920,062
Depreciation on Revaluation Surplus			(5,727,826)	5,727,826	-	-	-
Balance at 31 March 2025	2,340,000,000	8,016,892,026	3,281,403,266	7,229,695,378	20,867,990,670	1,491,360,323	22,359,350,993

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

Sd/-
Director

Sd/-
Managing Director

Sd/-
Chairman

ORION PHARMA LIMITED
Condensed Statement of Changes in Equity (Un-Audited)
For The Period Ended 31 March 2026

Particulars	Amount in BDT				
	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total
Balance at 01 July 2025	2,340,000,000	8,016,892,026	2,583,749,253	529,806,593	13,470,447,872
Net Profit after Tax	-	-	-	(90,596,516)	(90,596,516)
Fair Value Gain / (Loss) on Investment in Associate	-	-	72,175,686	-	72,175,686
Fair Value (Loss)/Gain on Marketable Securities	-	-	1,157,111	-	1,157,111
Adjustment for sale of Mkt. Securities	-	-	600	-	600
Share of Other Comprehensive Income	-	-	(55,286)	-	(55,286)
Adjustment of Deferred tax on Revaluation Surplus	-	-	229,706	-	229,706
Depreciation on Revaluation Surplus	-	-	(2,303,180)	2,303,180	-
Balance at 31 March 2026	2,340,000,000	8,016,892,026	2,654,953,890	441,513,257	13,453,359,173

For The Period Ended 31 March 2025

Particulars	Amount in BDT				
	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total
Balance at 01 July 2024	2,340,000,000	8,016,892,026	3,333,848,346	961,565,844	14,652,306,216
Net Profit after Tax	-	-	-	96,949,135	96,949,135
Cash Dividend for the year 2023-2024	-	-	-	(234,000,000)	(234,000,000)
Fair Value Gain / (Loss) on Investment in Associate	-	-	(394,584,467)	-	(394,584,467)
Fair Value (Loss)/Gain on Marketable Securities	-	-	(2,865,470)	-	(2,865,470)
Adjustment for sale of Mkt. Securities	-	-	1,350	-	1,350
Share of Other Comprehensive Income	-	-	314,467	-	314,467
Adjustment of Deferred tax on Revaluation Surplus	-	-	920,062	-	920,062
Depreciation on Revaluation Surplus	-	-	(4,224,332)	4,224,332	-
Balance at 31 March 2025	2,340,000,000	8,016,892,026	2,933,409,956	828,739,312	14,119,041,293

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

Sd/-
Director

Sd/-
Managing Director

Sd/-
Chairman

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Condensed Consolidated Statement of Cash Flows (Un-Audited)
For The Period Ended 31 March 2026

Particulars	Amount In BDT	
	July 2025 to March 2026	July 2024 to March 2025
A. Cash Flows from Operating Activities :		
Cash Received from Customers	2,298,543,755	3,223,297,591
Cash Paid to Suppliers	(468,498,827)	(1,195,692,445)
Cash Payment for Operating Expenses	(847,456,545)	(756,597,585)
Cash Generated from Operation	982,588,384	1,271,007,561
Income Taxes Paid	(31,445,391)	(37,529,764)
Net Cash Generated/(Used) from Operating Activities	951,142,993	1,233,477,797
B. Cash Flows from Investing Activities :		
Acquisition of Property, Plant & Equipment	(20,255,897)	(42,583,898)
Capital Work in Progress	(1,703,090,599)	(2,026,920,682)
Investment in Subsidiaries, Associate & Others	(4,770,961)	(5,900,665)
Interest, Dividend & Other Income	5,385,607	16,015,459
Net Cash Received/(Used) from Investing Activities	(1,722,731,850)	(2,059,389,786)
C. Cash Flows from Financing Activities :		
Long Term Loan Received/ (Repaid)	1,446,717,709	1,206,685,612
Short Term Loan Received/ (Repaid)	(436,193,497)	(198,379,822)
Lease obligation	(12,793,527)	(13,286,718)
Financial expenses paid	(216,354,810)	(235,507,570)
Dividend paid	(40,894)	(7,791,379)
Net Cash Received/(Used) from Financing Activities	781,334,980	751,720,123
Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	9,746,123	(74,191,866)
Cash & Cash Equivalents at the beginning of the period	72,100,511	147,730,453
Cash & Cash Equivalents at the end of the period	81,846,635	73,538,588
Number of Shares Used to Compute NOCFPS	234,000,000	234,000,000
Net Operating Cash Flow Per Share	4.06	5.27
	34.1	

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

Sd/-
Director

Sd/-
Managing Director

Sd/-
Chairman

ORION PHARMA LIMITED
Condensed Statement of Cash Flows (Un-Audited)
For The Period Ended 31 March 2026

Particulars	Amount In BDT	
	July 2025 to March 2026	July 2024 to March 2025
A. Cash Flows from Operating Activities :		
Cash Received from Customers	2,298,543,755	2,602,316,678
Cash paid to Suppliers	(833,914,289)	(839,966,757)
Cash Payment for Operating Expenses	(847,456,545)	(756,597,585)
Cash Generated from Operation	617,172,922	1,005,752,336
Income Taxes Paid	(31,445,391)	(37,529,764)
Net Cash Generated/(Used) from Operating Activities	585,727,531	968,222,572
B. Cash Flows from Investing Activities :		
Acquisition of Property, Plant & Equipment	(20,255,897)	(42,155,698)
Capital Work in Progress	(1,703,090,599)	(2,026,920,682)
Investment in Subsidiaries, Associate, Securities & Others	(4,770,961)	(5,900,665)
Interest, Dividend & Other Income	5,385,607	16,015,459
Net Cash Received/(Used) from Investing Activities	(1,722,731,850)	(2,058,961,586)
C. Cash Flows from Financing Activities :		
Long Term Loan Received/ (Repaid)	1,446,717,709	1,206,685,612
Short Term Loan Received/ (Repaid)	(84,115,048)	(9,230,951)
Lease obligation	(12,793,527)	(13,286,718)
Dividend paid	(40,894)	(7,791,379)
Interest Paid	(198,055,191)	(159,731,686)
Net Cash Received/(Used) from Financing Activities	1,151,713,049	1,016,644,878
Net Increase/(Decrease) in Cash & Cash Equivalentents (A+B+C)	14,708,729	(74,094,136)
Cash & Cash Equivalentents at the beginning of the period	50,719,499	128,341,450
Cash & Cash Equivalentents at the end of the period	65,428,228	54,247,314
Number of Shares Used to Compute NOCFPS	234,000,000	234,000,000
Net Operating Cash Flow Per Share	2.50	4.14

34a.1

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

Sd/-
Director

Sd/-
Managing Director

Sd/-
Chairman

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Selected Explanatory Notes to the Condensed Consolidated Financial Statements
For The Period Ended 31 March 2026 (Third Quarter)

1 Reporting Entity

1.1 Background of the Entity

Orion Pharma Limited, earlier called Orion Laboratories Limited was incorporated in 1965 as a private limited company. The Company was converted into a public limited company on 24 July 2010. The registered office of the company is at 153-154, Tejgaon I/A, Dhaka-1208, Bangladesh.

The Company is listed both with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE) on 20 March 2013.

1.2 Nature of Business

Orion Pharma Limited is engaged in the creation and discovery, development, manufacturing and marketing of pharmaceutical products including vaccines and health-related consumer products.

1.3 Subsidiary Companies

1.3.1 Orion Power Meghnaghat Limited

Orion Power Meghnaghat Ltd. was incorporated on 30 June 2010 as a public limited company under the Companies Act, 1994 with authorized share capital of Tk. 4,000,000,000 divided into 400,000,000 Ordinary shares of Tk. 10 each. The company implemented a 100 MW HFO Power based Plant on quick rental basis in Meghnaghat, Dhaka to supply electricity to national grid with machineries and equipment supplied by Wartsila OY, Finland. Orion Pharma Ltd. holds 95% of equity share of this company directly.

The company has set up a 100 MW HFO Power Plant on quick rental basis in Meghnaghat, Sonargaon, Narayanganj with machineries and equipment's supplied by Wartsila Finland OY for generation and supply of electricity. The company has signed the contract with Bangladesh Power Development Board (hereinafter referred as BPDB) acting as an off taker to supply power to them solely under the contract No. 09755 executed on June 30, 2010. According to the said contract, the Government will purchase the power for a period of five (5) years commencing from May 08, 2011. The contract has been extended for further five (5) years effective from May 09, 2016 vide memo no- 27.00.0000.071.14.035.2013.535 dated 01 December 2016. The contract then expired on 07 May 2021. The government renewed the contract for two (2) years effective from 24 March 2022 vide memo no - 27.11.0000.101.14.020.22-1697 dated: 10 April 2022. The purpose of this contract is to supply of Net Energy Output, under the terms and conditions provided "No Electricity, No Payment and also without any guaranteed Minimum Off-take" basis by Rental Power Company by BPDB which expired on 23 March 2024. As per memo No.: 27.11.0000.101.14.020.24-1099 dated: 29 April 2024, the company was instructed to resume and continue operation.

1.3.2 Dutch Bangla Power & Associates Limited

Dutch Bangla Power & Associates Ltd. was incorporated on 1 July 2010 as a public limited company under the Companies Act, 1994 with authorized share capital of Tk. 1,000,000,000 divided into 100,000,000 ordinary shares of Tk. 10 each. The Company was awarded by the Government of Bangladesh and BPDB to implement 100 MW HFO Power Plant on quick rental basis in Siddhirganj, Narayanganj to supply electricity to national grid with machineries and equipment supplied by Wartsila OY, Finland. Orion Pharma Ltd. holds 67% of equity share of this Company.

The company has set up a 100 MW HFO Power Plant on quick rental basis in Siddhirganj, Narayanganj with machineries and equipments supplied by Wartsila Finland OY for generation and supply of electricity. The company has signed the contract with Bangladesh Power Development Board (hereinafter referred as BPDB) acting as an off taker to supply power to them solely under the contract No. 09756 executed on July 01, 2010. According to the said contract, the Government will purchase the power for a period of five (5) years commencing from July 21, 2011. The contract has been extended for further five (5) years effective from 22 July 2016 vide memo no- 27.00.0000.071.14.122.2010.534 dated 01 December 2016. The contract then expired on 22 July 2021. The government renewed the contract for two (2) years effective from 24 March 2024 vide memo no - 27.11.0000.101.14.020.22-1696 dated: 10 April 2024. The purpose of this contract is to supply of Net Energy Output, under the terms and conditions provided "No Electricity, No Payment and also without any guaranteed Minimum Off-take" basis by Rental Power Company by BPDB which expired on 23 March 2024. As per memo No.: 27.11.0000.101.14.020.24-1100 dated: 29 April 2024, the company was instructed to resume and continue operation.

1.4 Associate Company

Orion Infusion Limited

Orion Infusion Limited is a public limited company incorporated in Bangladesh on May 05, 1983 and is now operating under the banner of Orion Group. Other shareholders of the company are sponsor shareholders, foreign investors, financial institutions and general public.

The Company was listed with Dhaka Stock Exchange Limited (DSE) on 05 October 1994 and Chittagong Stock Exchange Limited (CSE) on 22 September 1996. Orion Pharma Ltd. holds 21.76 % of equity share of this company directly.

2 Basis of Preparation

2.1 Statement of Compliance

These Condensed Interim Financial Statements of the company comprised the company's and its subsidiaries (together referred to as the 'Group' and individually as 'Group entities') and the Group's interest in associates have been prepared in accordance with International Financial Reporting Standards (IFRSs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB), in particular International Accounting Standard (IAS) 34: *Interim Financial Reporting*, the Companies Act 1994, Securities and Exchange Rules 1987 and other applicable laws and regulations.

2.2 Components of the Condensed Financial Statements

According to IAS-34 'Interim Financial Reporting', these interim financial statements include the following components-

- i. Condensed Consolidated Statement of Financial Position
- ii. Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
- iii. Condensed Consolidated Statement of Changes in Equity
- iv. Condensed Consolidated Statement of Cash Flows
- v. Selected Explanatory Notes to the Condensed Consolidated Financial Statements

2.3 Basis of Measurement

The financial statements have been prepared on historical cost basis except for certain assets which are stated either at revalued amount or fair market value.

2.4 Functional and Presentation Currency

The financial statements are prepared and presented in Bangladesh Taka (Taka/Tk./BDT), which is the company's functional and presentation currency. All amounts have been rounded off to the nearest integer.

2.5 Reporting Period

These Condensed Interim Financial Statements of the company cover the period from 1 July 2025 to 31 March 2026.

2.6 Date of Authorization

The financial statements were authorized for issue by the Board of Directors in its meeting held on 29 April 2026 for publication.

2.7 Events after the reporting period

Information regarding subsidiary companies

For this quarter there was no such issue.

3 Accounting Policies and Methods of Computations

The accounting policies and methods of computations followed in preparing these financial statements are same as those used in the annual financial statements prepared and published for the year ended 30 June 2025.

4 Subsequent Events

No material events occurred after the reporting date, non-disclosure of which could affect the ability of the users of the financial statements to make proper evaluation and decision.

5 Acquisition of Property, Plant & Equipments of Orion Pharma Ltd. and its subsidiaries during the Period.

Discloser as per BSEC Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018.

SL No.	Particulars	Amount in BDT	
		July 2025-March 2026	July 2024-March 2025
i	Factory & Office Building	756,594	35,541,604
ii	Plant & Machinery	12,967,332	4,450,005
iii	Furniture & Fixtures	199,400	6,100
iv	Office Equipment	6,332,571	2,564,322
v	Road & Road Development	-	21,866
	Total	20,255,897	42,583,898

SL No.	Particulars	Amount in BDT	
		31-Mar-26	30-Jun-25
6.	Property, plant and equipment		
	Opening balance	20,646,613,960	21,077,115,349
	Add: Addition during the period	20,255,897	64,170,941
	Transfer from Capital work in Progress	-	122,948,544
	Less: Sale /disposal during the period	-	(169,743)
		20,666,869,857	21,264,065,091
	Less: Depreciation charged during the period	(412,634,240)	(617,451,131)
	Written down value	20,254,235,618	20,646,613,960

6a.	Property, plant and equipment		
	Opening balance	14,888,931,168	15,265,180,705
	Add: Addition during the period	20,255,897	63,742,741
	Transfer from Capital work in Progress	-	122,948,544
	Less: Sale /disposal during the period	-	(169,743)
		14,909,187,065	15,451,702,247
	Less: Depreciation charged during the period	(403,610,047)	(562,771,079)
	Written down value	14,505,577,017	14,888,931,168

7.	Right of use assets		
	Opening Balance	180,376,226	143,942,706
	Add: Addition during the period	12,352,456	36,433,520
		192,728,682	180,376,226
	Less: Disposal/ adjustment	-	-
		192,728,682	180,376,226
	Amortization		
	Opening balance	136,532,556	119,580,834
	Addition during the period	12,934,552	16,951,722
		149,467,108	136,532,556
	Written down value	43,261,575	43,843,671

8.	Capital Work in Progress		
	Opening balance	10,246,869,406	7,849,966,393
	Add: Addition during the period	1,703,090,599	2,633,787,608
	Transfer to Property, plant and equipment	-	(122,948,544)
	Previous years adjustment	-	(113,936,051)
		11,949,960,005	10,246,869,406

Name of the subsidiary company	Number of shares	Share holding (%)	Amount in BDT	
			31-Mar-26	30-Jun-25
Orion Power Meghnaghat Ltd.	95,000,000	95.00	950,000,000	950,000,000
Dutch Bangla Power & Associates Ltd.	6,700,000	67.00	67,000,000	67,000,000
Total			1,017,000,000	1,017,000,000

Investment in subsidiaries are stated at cost.

10.	Investment in associate		
	Orion Infusion Limited		
	Opening balance	1,389,691,000	2,128,615,000
	Add: Share of profit during the period	6,290,600	7,619,600
	Less: Dividend during the period	-	(5,316,000)
	Add: Share of other comprehensive income	(55,286)	61,920
	Add: Fair value adjustment	72,175,686	(741,289,520)
		1,468,102,000	1,389,691,000

SL No.	Particulars	Amount in BDT	
		31-Mar-26	30-Jun-25
11. Other investment			
	Investment in marketable securities (Note 11.1)	12,943,039	11,785,328
	Investment in non-Quoted Shares (Note 11.2)	5,920,240,676	5,920,240,676
		5,933,183,715	5,932,026,004
11.1 Investment in marketable securities			
	AB Investment Limited.	1,312,704	1,312,704
	Bank Asia Securities Limited.	4,536,420	3,975,961
	LankaBangla Securities Ltd.	7,093,915	6,496,663
		12,943,039	11,785,328
11.2 Investment in non-quoted shares			
	Orion Power Khulna Limited.	500,000	500,000
	Orion Power Dhaka Limited.	500,000	500,000
	ICB Islami Bank Limited	246,000	246,000
	Orion Infrastructure Limited.	2,117,209,676	2,117,209,676
	Orion Power Unit - 2 Dhaka Ltd.	3,801,785,000	3,801,785,000
		5,920,240,676	5,920,240,676
11a Other investment			
	Investment in marketable securities (Note 11a.1)	12,943,039	11,785,328
	Investment in non-Quoted Shares (Note 11a.2)	2,120,240,676	2,120,240,676
		2,133,183,715	2,132,026,004
11a.1 Investment in marketable securities			
	AB Investment Limited.	1,312,704	1,312,704
	Bank Asia Securities Limited.	4,536,420	3,975,961
	LankaBangla Securities Ltd.	7,093,915	6,496,663
		12,943,039	11,785,328
11a.2 Investment in non-quoted shares			
	Orion Power Khulna Limited.	500,000	500,000
	Orion Power Dhaka Limited.	500,000	500,000
	ICB Islami Bank Limited	246,000	246,000
	Orion Infrastructure Limited.	2,117,209,676	2,117,209,676
	Orion Power Unit - 2 Dhaka Ltd.	1,785,000	1,785,000
		2,120,240,676	2,120,240,676
12. Inventories			
	Raw materials	140,863,061	163,552,185
	Packing materials	17,891,434	110,995,829
	Work-in-process	56,349,923	29,518,504
	Finished goods	178,747,010	170,591,006
	Printing Stationeries	410,595	7,115,895
	Promotional materials	17,348,376	26,244,052
	Material in transit	102,796,101	70,596,535
	Spare parts	217,503,662	472,148,524
	Inventory HFO & LFO	345,543,627	454,440,667
		1,077,453,790	1,505,203,198
12.a Inventories			
	Raw materials	140,863,061	163,552,185
	Packing materials	17,891,434	110,995,829
	Work-in-process	56,349,923	29,518,504
	Finished goods	178,747,010	170,591,006
	Printing Stationeries	410,595	7,115,895
	Promotional materials	17,348,376	26,244,052
	Material in transit	102,796,101	70,596,535
		514,406,501	578,614,007

SL No.	Particulars	Amount in BDT	
		31-Mar-26	30-Jun-25
13.	Trade & other receivables		
	Trade receivables	4,373,199,817	4,390,462,955
	Other receivables (Note-13.1)	10,972,249,867	10,655,531,772
		15,345,449,685	15,045,994,727

Trade receivables are unsecured, considered good and recoverable within one year. Classification schedules as required by schedule XI of Companies Act 1994 are as follows:

Ageing of the above balance is as follows:

Below 180 days	4,373,199,817	4,390,462,955
Above 180 days	-	-
	4,373,199,817	4,390,462,955

SL. No.	Particulars	Amount in BDT	
		31-Mar-26	30-Jun-25
I	Trade receivables considered good in respect of which the company is fully secured	4,373,199,817	4,390,462,955
II	Trade receivables considered good in respect of which the company holds no security other than the debtor personal security	-	-
III	Trade receivables considered doubtful or bad	-	-
IV	Trade receivables due by any director or other officer of the company	-	-
V	Trade receivables due by common management	-	-
VI	The maximum amount of receivable due by any director or other officer of the company	-	-
	Total	4,373,199,817	4,390,462,955

13.1 Other receivables

Claim receivables, insurance & others	3,641,490	4,352,154
Dividend receivable	-	5,316,000
Interest on FDR	822,993	808,255
Other receivables	1,869,353,839	1,872,410,611
Current account with other related companies (Note. 13.1.1)	9,098,431,545	8,772,644,752
	10,972,249,867	10,655,531,772

13.1.1 Current account with other related companies

Noakhali Gold Food Ltd.	10,859,928	10,859,928
Orion Properties Ltd.	23,550,142	23,550,142
Orion Gas Limited	93,611,272	90,911,272
Orion Power Khulna Ltd.	1,076,950,154	1,076,950,154
Orion Power Dhaka Ltd.	2,370,421,740	2,370,421,740
Jafflong Tea Company Ltd.	73,302,850	73,302,850
Orion Agro Product Ltd.	275,775,350	275,775,350
Interior Accom Consortium Ltd.	85,407,892	85,407,892
Digital Power & Associate Ltd.	1,539,951,662	1,227,520,659
Orion Footwear Ltd.	263,412,307	263,412,307
Panbo Bangla Mashroom Ltd.	38,128,200	38,128,200
Orion Power Unit 2 Dhaka Ltd.	952,641,688	952,331,474
Orion Home Appliance Ltd.	139,014,584	139,326,926
Orion Hospitals Ltd.	26,222,300	26,222,300
Orion Power Rupsha Ltd.	62,255,465	75,519,905
Energon Renewable (BD) Ltd.	683,194,670	683,407,792
Orion Quaderia Textiles Ltd.	187,293,090	187,910,000
Orion Tea Company Ltd	379,580,373	379,580,373
SAZKA Natural Care Ltd.	108,663,500	108,663,500
Orion Power Sonargaon Ltd	686,607,162	661,859,989
Orion Knit Textiles Ltd.	21,587,217	21,582,000
	9,098,431,545	8,772,644,752

SL No.	Particulars	Amount in BDT	
		31-Mar-26	30-Jun-25
13.a	Trade & other receivables		
	Trade receivables	338,850,703	356,113,840
	Other receivables (Note - 13a.1)	9,197,180,597	9,204,716,783
		9,536,031,300	9,560,830,623

Trade receivables are unsecured, considered good and recoverable within one year. Classification schedules as required by schedule XI of Companies Act 1994 are as follows:

Ageing of the above balance is as follows:

Below 180 days	338,850,703	356,113,840
Above 180 days	-	-
	338,850,703	356,113,840

SL No	Particulars	Amount in BDT	
		31-Mar-26	30-Jun-25
I	Trade receivables considered good in respect of which the company is fully secured	338,850,703	356,113,840
II	Trade receivables considered good in respect of which the company holds no security other than the debtor personal security		-
III	Trade receivables considered doubtful or bad		-
IV	Trade receivables due by any director or other officer of the company		-
V	Trade receivables due by common management		-
VI	The maximum amount of receivable due by any director or other officer of the company		-
	Total	338,850,703	356,113,840

13a.1 Other receivables

Claim Receivables: Insurance & Others	3,641,490	4,352,154
Dividend receivable	-	5,316,000
Interest on FDR	822,993	808,255
Other receivables	1,589,826,900	1,589,826,900
Current account with subsidiaries (13a.1.1)	346,805,959	346,805,959
Current account with other related companies (13a.1.2)	7,256,083,255	7,257,607,515
	9,197,180,597	9,204,716,783

13a.1.1 Current account with subsidiaries

Dutch Bangla Power & Associates Limited.	346,805,959	346,805,959
	346,805,959	346,805,959

13a.1.2 Current account with other related companies

Orion Properties Ltd.	21,780,585	21,780,585
Orion Power Khulna Ltd.	1,076,950,154	1,076,950,154
Orion Power Dhaka Ltd.	2,284,377,084	2,284,377,084
Interior Accom Consortium Ltd.	118,564,892	118,564,892
Orion Agro Product Ltd.	267,922,512	267,922,512
Orion Power Unit -2 Dhaka Ltd.	1,062,560,717	1,062,250,503
Digital Power & Associates Ltd.	196,121,737	196,111,884
Orion Hospitals Ltd.	21,222,300	21,222,300
Energon Renewables (BD) Ltd.	698,494,670	698,707,792
Orion Home Appliances Ltd.	131,207,088	131,519,430
SAZKA Natural Care Ltd.	108,663,500	108,663,500
Orion Gas Ltd.	41,711,272	41,711,272
Panbo Bangla Mushroom Ltd	38,128,200	38,128,200
Orion Footwear Ltd.	124,750,145	124,750,145
Orion Tea Company Ltd	379,580,373	379,580,373
Orion Power Sonargaon Ltd	484,273,241	484,980,411
Jafflong Tea Company Ltd.	70,894,479	70,894,479
Orion Knit Textiles Ltd.	21,587,217	21,582,000
Orion Quaderia Textiles Ltd	107,293,090	107,910,000
	7,256,083,255	7,257,607,515

SL No.	Particulars	Amount in BDT	
		31-Mar-26	30-Jun-25
14.	Advances, deposits and prepayments		
	Advances:		
	Advance income tax (Note-14.1)	370,786,559	339,129,507
	Advance imprest money	158,000	145,000
	Advance motor cycle	2,726,585	4,158,502
	Advance - car loan	284,808	284,808
	Collection advance	16,934,685	12,544,063
	Advance to C&F agents	8,045,036	8,430,598
	Advance office rent	4,225,697	3,763,241
	Advance against land purchase	97,260,635	97,260,635
	Advance to employee	4,516,650	4,146,413
	Other advance	84,206	89,206
	Advance Cash Purchase	1,592,291	-
	Advance to Supplier	168,760,128	145,514,697
	Machinery in Transit	9,620,538	5,258,127
		684,995,818	620,724,796
	Deposits:		
	Earnest money	9,780,000	9,868,691
	Security deposit	42,221,743	42,272,933
	Bank guarantee	58,530,166	58,530,166
	L/C Margin & Balance	127,972,434	526,567
	Lease deposit	254,133	127,700,000
		238,758,477	238,898,358
	Prepayments:		
	Bank guranttee,commission & charge	-	-
		-	-
		923,754,294	859,623,154
14.1	Advance income tax		
	Opening balance	339,129,507	295,975,607
	Add: Addition during the period	31,657,052	43,153,900
	Closing balance	370,786,559	339,129,507
14.a	Advances, deposits & prepayments		
	Advances:		
	Advance income tax (Note -14a.1)	367,506,983	336,061,592
	Advance imprest money	158,000	145,000
	Motor cycle advance	2,726,585	4,158,502
	Advance - car loan	284,808	284,808
	Collection advance	16,934,685	12,544,063
	Advance to C&F agents	8,045,036	8,430,598
	Advance office rent	4,225,697	3,763,241
	Advance against land purchase	97,260,635	97,260,635
	Advance to Employee	4,330,810	3,814,576
	Others Advance	84,206	89,206
	Advance Cash Purchase	1,592,291	-
	Advance Paid to Suppliers	145,025,437	120,908,974
	Machinery in Transit	9,620,538	5,258,127
		657,795,710	592,719,322
	Deposits		
	Earnest money	9,780,000	9,868,691
	Security deposit	42,221,743	42,272,933
	Bank guarantee	3,715,790	3,715,790
	Lease deposit	254,133	254,133
	L/C Margin & Balance	127,700,000	127,700,000
		183,671,666	183,811,547
		841,467,377	776,530,869

SL No.	Particulars	Amount in BDT	
		31-Mar-26	30-Jun-25
14a.1	Advance income tax		
	Opening balance	336,061,592	293,412,515
	Addition during the period	31,445,391	42,649,077
	Closing balance	367,506,983	336,061,592
15.	Fixed deposit with banks		
	Social Islami Bank Limited., Principal Branch, Dhaka.	11,904,840	11,220,610
	Agrani Bank Ltd.	54,585,156	42,962,240
		66,489,996	54,182,849
16.	Cash & cash equivalents		
	Cash in hand (Note -16.1)	7,730,653	5,736,755
	Cash at B/O account (Note -16.2)	64,172	64,622
		7,794,825	5,801,377
	Balance with banks on account		
	Current account	67,237,815	60,013,180
	Short term deposit account	6,813,995	6,285,954
		74,051,809	66,299,134
		81,846,635	72,100,511
16.1	Cash in hand		
	Head office	1,932,711	856,653
	Depot office	5,797,942	4,880,102
		7,730,653	5,736,755
16.2	Cash at B/O account		
	Bank Asia Securities Limited.	19,399	19,549
	Jahan Securities Limited.	474	624
	LankaBangla Securities Ltd.	42,099	42,249
	Shanta Securities Ltd.	2,200	2,200
		64,172	64,622
16.a	Cash and cash equivalents		
	Cash in hand (Note -16a.1)	4,509,808	4,018,649
	Cash at B/O account (Note -16a.2)	61,972	62,422
		4,571,780	4,081,071
	Cash at Bank:		
	Current account	54,042,454	40,352,473
	Short term deposit account	6,813,995	6,285,954
		60,856,449	46,638,427
		65,428,228	50,719,499
16a.1	Cash in hand		
	Head office - central cash & main cash	445,516	91,826
	Depot office - petty cash	4,064,292	3,926,824
		4,509,808	4,018,649
16a.2	Cash at B/O account		
	Bank Asia Securities Limited	19,399	19,549
	LankaBangla Securities Ltd.	42,099	42,249
	Jahan Securities Limited	474	624
		61,972	62,422
17.	Share capital		
	Authorized capital		
	500,000,000 ordinary shares of Tk. 10 each	5,000,000,000	5,000,000,000
	Issued, subscribed and paid-up capital		
	234,000,000 ordinary shares of Tk. 10 each	2,340,000,000	2,340,000,000

SL No.	Particulars	Amount in BDT	
		31-Mar-26	30-Jun-25

Shareholding position of the company

Range of Shareholding	Number of Shareholders	Number of Shares	% of holding	
			31-Mar-26	30-Jun-25
Up to 500 Shares	22,825	3,237,287	1.38%	1.50%
501 to 5,000 Shares	11,030	21,156,015	9.04%	9.73%
5001 to 10,000 Shares	1,942	14,430,152	6.17%	6.42%
10,001 to 20,000 Shares	1,137	16,321,176	6.97%	7.18%
20,001 to above	1,083	178,855,370	76.43%	75.17%
Total	38,017	234,000,000	100%	100%

Categories of shareholders	Number of Shareholders	Number of Shares	% of holding	
			31-Mar-26	30-Jun-25
Sponsors	5	74,841,600	31.98%	31.98%
Foreign Investor	133	261,109	0.11%	0.08%
Financial institutions	488	48,952,733	20.92%	21.41%
General public	37,391	109,944,558	46.98%	46.53%
Total	38,017	234,000,000	100%	100%

Orion Power Meghnaghat Limited	Number of Shares	Face Value	% of holding	
			31-Mar-26	30-Jun-25
Orion Pharma Limited	95,000,000	950,000,000	95.00%	95.00%
Integral Energy Limited	3,000,000	30,000,000	3.00%	3.00%
Jafflong Tea Company Limited	500,000	5,000,000	0.50%	0.50%
Mr. Mohammad Obaidul Karim	500,000	5,000,000	0.50%	0.50%
Mr. Salman Obaidul Karim	600,000	6,000,000	0.60%	0.60%
Mrs. Arzuda Karim	350,000	3,500,000	0.35%	0.35%
Haarhuis Generation B.V.	50,000	500,000	0.05%	0.05%
Total	100,000,000	1,000,000,000	100%	100%

Dutch Bangla Power & Associates Limited	Number of Shares	Face Value	% of holding	
			31-Mar-26	30-Jun-25
Orion Pharma Limited	6,700,000	67,000,000	67.00%	67.00%
Shenzhen Nanshan Power Co. Ltd.	50,000	500,000	0.50%	0.50%
Mohammad Obaidul Karim	100,000	1,000,000	1.00%	1.00%
Salman Obaidul Karim	3,087,500	30,875,000	30.88%	30.88%
Orion Tea Company Ltd.	50,000	500,000	0.50%	0.50%
Jafflong Tea Co. Ltd.	2,500	25,000	0.03%	0.03%
Mrs. Arzuda Karim	10,000	100,000	0.10%	0.10%
Total	10,000,000	100,000,000	100%	100%

18. Reserves

Fair value gain/(loss) on investment in associate (Note -18.1)	1,364,685,061	1,292,509,375
Fair value gain/(loss) on marketable securities (Note -18.2)	(14,648,154)	(15,690,094)
Share of other comprehensive income of associate (Note - 18.3)	6,781,507	6,836,794
Revaluation surplus on property, plant and equipment (Note -18.4)	1,645,681,133	1,647,970,215
	<u>3,002,499,547</u>	<u>2,931,626,290</u>

18.1 Fair value gain on investment in associate

Opening balance	1,292,509,375	2,033,798,895
Fair value gain/ (loss) during the period	72,175,686	(741,289,520)
	<u>1,364,685,061</u>	<u>1,292,509,375</u>

18.2 Fair value gain/(loss) on marketable securities

Opening balance	(15,690,094)	(11,606,178)
Adjustment of sale of marketable securities	600	1,350
Fair value gain/(loss) on marketable securities (Note - 18.2.1)	1,157,111	(4,539,035)
Transferred to deferred tax assets/(liabilities)	(115,771)	453,768
	<u>(14,648,154)</u>	<u>(15,690,094)</u>

SL No.	Particulars	Amount in BDT	
		31-Mar-26	30-Jun-25
18.2.1	Fair value gain/(loss) on marketable securities during the period		
	Unrealized gain/(loss) position (closing)	(16,275,727)	(17,433,438)
	Unrealized gain/(loss) position (opening)	(17,433,438)	(12,895,753)
	Total change during the period	1,157,711	(4,537,685)
	Fair value adjustment for sale of securities (realized loss)	(600)	(1,350)
	Unrealized gain/(loss) during the period	1,157,111	(4,539,035)
18.3	Share of other comprehensive income		
	Opening balance	6,836,794	6,774,874
	Add: Addition during the period	(55,286)	61,920
		6,781,507	6,836,794
18.4	Revaluation surplus on property, plant & equipment		
	Opening balance	1,647,970,215	1,654,377,559
	Adjustment during the period to retained earnings for depreciation	(2,634,560)	(7,252,210)
	Adjustment of deferred tax on revaluation surplus	345,477	844,866
		1,645,681,133	1,647,970,215
18.a	Reserve		
	Fair value gain on investment in associates (Note - 18a.1)	1,364,685,060	1,292,509,374
	Fair value gain/(loss) on marketable securities (Note - 18a.2)	(14,648,154)	(15,690,093)
	Share of other comprehensive income (Note - 18a.3)	6,781,508	6,836,794
	Revaluation surplus on property, plant & equipment (Note - 18a.4)	1,298,135,475	1,300,093,178
		2,654,953,890	2,583,749,253
18a.1	Fair value gain on investment in associates		
	Opening balance	1,292,509,374	2,033,798,894
	Fair value gain/(loss) during the period	72,175,686	(741,289,520)
		1,364,685,060	1,292,509,374
18a.2	Fair value gain/(loss) on marketable securities		
	Opening balance	(15,690,093)	(11,606,177)
	Adjustment of sale of marketable securities	600	1,350
	Fair value gain/(loss) on marketable securities D/Y (Note - 18a.2.1)	1,157,111	(4,539,035)
	Transferred to deferred tax assets/(liabilities)	(115,771)	453,768
		(14,648,154)	(15,690,093)
18a.2.1	Fair value gain/(loss) on marketable securities during the period		
	Unrealized gain/(loss) position (closing)	(16,275,727)	(17,433,438)
	Unrealized gain/(loss) position (opening)	(17,433,438)	(12,895,753)
	Fair value adjustment for sale of securities realized gain/(loss)	(600)	(1,350)
	Unrealized gain/(loss) during the period	1,157,111	(4,539,035)
18a.3	Share of other comprehensive income		
	Opening balance	6,836,794	6,774,874
	Add: Addition during the period	(55,286)	61,920
		6,781,508	6,836,794
18a.4	Revaluation surplus on property, plant & equipment		
	Opening balance	1,300,093,178	1,304,880,755
	Adjustment during the period to retained earnings for depreciation	(2,303,180)	(5,632,443)
	Adjustment of deferred tax on revaluation surplus	345,477	844,866
		1,298,135,475	1,300,093,178
19.	Retained earnings		
	Opening balance	6,857,317,431	7,499,339,162
	Net profit after tax	(221,394,386)	(415,280,715)
	Dividend for the period	-	(234,000,000)
	Adjustment for depreciation on revaluation surplus	2,634,560	7,252,210
	Adjustment for Right of use Assets	-	6,775
		6,638,557,605	6,857,317,431

SL No.	Particulars	Amount in BDT	
		31-Mar-26	30-Jun-25
19.a	Retained Earnings		
	Opening balance	529,806,593	961,565,844
	Net profit after tax	(90,596,516)	(203,398,468)
	Dividend for the period	-	(234,000,000)
	Adjustment for depreciation on revaluation surplus	2,303,180	5,632,443
	Adjustment for Right of use Assets	-	6,775
		441,513,257	529,806,593
20.	Non-controlling interest		
	Opening balance	1,472,257,451	1,543,272,725
	Share of operating profit	(38,492,426)	(71,015,274)
	Closing balance	1,433,765,025	1,472,257,451
21	Syndicated loan and other long term loans		
	Agrani Bank Ltd. -BMRE	5,639,091,799	5,317,974,799
	Social Islami Bank Ltd	1,523,965,210	1,506,647,035
	Term Loan -SBLC Agrani Bank Ltd	3,684,000,000	3,684,000,000
	AL-Arafa Islami Bank Ltd.	2,543,128,392	2,391,767,588
	Rupali Bank Ltd.	3,385,832,111	3,155,526,054
	Janata Bank Ltd	5,826,830,196	5,262,348,921
	Agrani Bank Ltd.	2,409,701,714	2,411,548,896
	United Commercial Bank Ltd	1,570,783,541	1,406,801,959
		26,583,332,962	25,136,615,253
21.a	Long term loan		
	Agrani Bank Ltd. -BMRE	5,639,091,799	5,317,974,799
	Social Islami Bank Ltd.	1,523,965,210	1,506,647,035
	Term Loan -SBLC Agrani Bank Ltd.	3,684,000,000	3,684,000,000
	AL-Arafa Islami Bank Ltd.	2,543,128,392	2,391,767,588
	Rupali Bank Ltd.	3,385,832,111	3,155,526,054
	Janata Bank Ltd	5,826,830,196	5,262,348,921
	Agrani Bank Ltd.	2,409,701,714	2,411,548,896
	United Commercial Bank Ltd	1,570,783,541	1,406,801,959
		26,583,332,962	25,136,615,253
22	Lease obligation		
	Lease obligation (Office rent)	46,180,446	46,621,517
		46,180,446	46,621,517
	Current portion of lease obligation (22.1)	(14,019,887)	(14,932,954)
		32,160,559	31,688,563
22.1	Current portion of lease obligation		
	Lease obligation (Office rent)	14,019,887	14,932,954
		14,019,887	14,932,954
23	Deferred tax liability		
	Opening balance	402,122,053	315,432,156
	Adjustment for deferred tax expenses /(income) (Note-23.1)	51,366,932	87,988,532
	Adjustment for deferred tax on revaluation surplus (Note-23.2)	(229,706)	(1,298,635)
		453,259,279	402,122,053
23.1	Adjustment during the year on deferred tax on PPE		
	Deferred tax liability on PPE (closing)	408,666,668	357,299,736
	Deferred tax liability on PPE (opening)	357,299,736	269,311,204
	Deferred tax expenses/(income)	51,366,932	87,988,532

SL No.	Particulars		Amount in BDT		
			31-Mar-26	30-Jun-25	
		WDV as on 31 March 2026		Amount in BDT	
	Particular	Tax Base	Accounting Base	Deferred Tax Liability as on 31 March 2026	Deferred Tax Liability as on 30 June 2025
	Written down value of property, plant and equipment	8,503,803,420	10,320,099,724	(408,666,668)	(357,299,736)
23.2	Adjustment of deferred tax on revaluation Surplus				
	Deferred tax liability on revaluation surplus (Closing) (Note-23.2.1)			44,592,610	44,822,316
	Deferred tax liability on revaluation surplus (Opening)			44,822,316	46,120,951
	Deferred tax expenses/(income)			(229,706)	(1,298,635)
23.2.1	Adjustment of deferred tax on revaluation surplus				
		WDV as on 31 March 2026		Amount in BDT	
	Particulars	Tax Base	Accounting Base	Deferred Tax Liability as on 31 March 2026	Deferred Tax Liability as on 30 June 2025
	Revaluation reserved on land & land development	-	1,298,728,729	(38,961,862)	(38,961,862)
	Revaluation reserved factory & office building	-	38,467,129	(5,770,069)	(5,994,877)
	Revaluation reserved plant & machinery	-	9,921,679	(1,488,252)	(1,608,921)
	Revaluation reserve on marketable securities	-	(16,275,727)	1,627,573	1,743,344
	Total	-	1,330,841,811	(44,592,610)	(44,822,316)
24.	Short term loans				
	Cash credit (Hypo) Agrani Bank Ltd.			356,463,511	361,337,762
	LTR Agrani Bank Ltd.,WASA Corporate Branch			-	79,240,947
	Loan against marketable securities			53,121,814	53,121,664
				409,585,325	493,700,373
25	Trade and other payables				
	Goods suppliers & manufacturer			5,583,214,874	5,587,057,619
	Other payable			445,547,730	357,906,730
	Current account with inter companies (Note -25.1)			1,131,811,569	1,123,109,881
				7,160,574,173	7,068,074,231
25.1	Current account with inter companies				
	Orion Capital Ltd.			18,420,000	18,420,000
	Orion Oil & Shipping Ltd.			1,110,391,569	1,101,689,881
	Orion Ship Management Ltd.			3,000,000	3,000,000
				1,131,811,569	1,123,109,881
25.a	Trade and other payables				
	Goods suppliers & manufacturer			373,158,643	374,104,181
	Other payables			81,177,807	89,761,488
				454,336,451	463,865,669
26	Employee benefits				
	Workers welfare fund (Note -26.1)			10,943,007	10,943,007
	Bangladesh workers welfare foundation (Note -26.2)			17,669,870	17,669,870
	Workers profit participation fund (Note -26.3)			70,196,433	74,138,871
				98,809,311	102,751,749

SL No.	Particulars	Amount in BDT	
		31-Mar-26	30-Jun-25
26.1	Workers welfare fund		
	Opening balance	10,943,007	15,817,871
	Add: Addition for the period	-	-
	Less: Payment during the period	-	(4,874,863)
		10,943,007	10,943,007
26.2	Bangladesh workers welfare foundation		
	Opening balance	17,669,870	18,355,714
	Add: Addition for the year	-	-
	Less: Payment during the period	-	(685,844)
		17,669,870	17,669,870
26.3	Workers profit participation fund		
	Opening balance	74,138,871	113,060,868
	Add: Addition for the year	-	-
	Less: Payment during the period	(3,942,438)	(38,921,997)
		70,196,433	74,138,871
26.a	Employee benefits		
	Workers welfare fund (Note -26.a.1)	189,704	189,704
	Bangladesh workers welfare foundation (Note -26.a.2)	10,758,218	10,758,218
	Workers profit participation fund (Note -26.a.3)	362,449	362,449
		11,310,372	11,310,372
26.a.1	Workers welfare fund		
	Opening Balance	189,704	5,064,567
	Addition during the period	-	-
	Payment during the period	-	(4,874,863)
		189,704	189,704
26.a.2	Bangladesh workers welfare foundation		
	Opening balance	10,758,218	10,758,218
	Addition for the period	-	-
	Payment during the period	-	-
		10,758,218	10,758,218
26.a.3	Workers profit participation fund		
	Opening Balance	362,449	34,861,355
	Addition during the period	-	-
	Payment during the period	-	(34,498,906)
		362,449	362,449
27.	Accrued expenses		
	Salary and wages payable	100,917,714	94,761,367
	Director remuneration payable	41,692,699	30,681,459
	Depot expenses payable	6,000,000	1,610,381
	Telephone & mobile bill payable	5,383,157	5,100,534
	Payable for final settlement of employee	17,123,732	16,998,285
	Utilities payable	8,819,936	11,087,813
	Provision for income tax (Note 27.1)	334,876,402	321,156,401
	Statutory Audit fees	-	1,196,000
	Corporate governance audit fees	-	69,000
	Retention money	3,618,656	3,618,656
	Interest payable on Mashreq Dubai	14,020,816	14,020,816
		532,453,112	500,300,711

SL No.	Particulars	Amount in BDT	
		31-Mar-26	30-Jun-25
27.1	Provision for income tax		
	Opening balance	321,156,401	304,490,093
	Add: Addition during the period	13,720,001	19,666,307
		334,876,402	324,156,401
	Less: Payment/ AIT adjustment during the period	-	(3,000,000)
		334,876,402	321,156,401
27.a	Accrued expenses		
	Salary and wages payable	71,206,373	70,079,741
	Depot expenses payable	1,711,168	1,610,381
	Director remuneration payable	6,000,000	3,300,000
	Telephone & mobile bill payable	5,383,157	5,100,534
	Payable for final settlement of employee	17,123,732	16,998,285
	Utilities payable	8,819,936	11,087,813
	Provision for income tax (Note - 26.a.1)	334,876,402	321,156,401
	Statutory Audit fees	-	690,000
	Corporate governance audit fees	-	69,000
		445,120,768	430,092,154
27.a.1	Provision for income tax		
	Opening balance	321,156,401	304,490,093
	Add: Addition during the period	13,720,001	19,666,307
		334,876,402	324,156,401
	Less: Payment/ AIT adjustment during the period	-	(3,000,000)
	Closing balance	334,876,402	321,156,401

SL No.	Particulars	Amount in BDT	
		July 2025 to March 2026	July 2024 to March 2025
28. Revenue from net sales			
Local sales	2,128,682,812	2,362,333,655	
Export sales	152,597,806	172,105,953	
Revenue from power generation (Note-28.1)	-	817,570,779	
	2,281,280,618	3,352,010,387	
28.1 Revenue from power generation			
Reference energy price (variable - O&M)	-	137,345,898	
HFO received from OOSL & BPDB	-	680,224,881	
	-	817,570,779	
28.a Revenue from net sales			
Local sales	2,128,682,812	2,362,333,655	
Export sales	152,597,806	172,105,953	
	2,281,280,618	2,534,439,608	
29 Financial expense			
Agrani Bank Limited, Cash Credit (Hypo.)	24,434,426	33,613,562	
Agrani Bank Limited, LTR	2,119,406	13,853,165	
Finance cost on lease obligation (Office rent)	2,790,652	2,220,147	
Bank Charge ,commission & Fees	-	20,214,869	
Interest on Long Term Borrowing	187,010,326	165,605,828	
	216,354,810	235,507,570	
29a Financial expenses			
Agrani Bank Limited, Cash Credit (Hypo.)	24,434,426	33,613,562	
Agrani Bank Limited, LTR	2,119,406	13,853,165	
Finance cost on lease obligation (Office rent)	2,790,652	2,220,147	
Bank Commission, Fees, VAT and Other Charges	-	9,394,948	
Interest on Term Loan	168,710,707	100,649,865	
	198,055,191	159,731,686	
30. Interest & other income			
Interest on FDR	4,017,040	5,002,624	
Dividend income	271,085	2,621,375	
Others Income	1,098,083	4,776,809	
Cash Incentive	-	3,616,000	
Gain/(loss) on sale of marketable securities (Note 30.a.1)	(600)	(1,350)	
	5,385,607	16,015,459	
30.a Interest & other income			
Interest on FDR	4,017,040	5,002,624	
Dividend income	271,085	2,621,375	
Others Income	1,098,083	4,776,809	
Cash Incentive	-	3,616,000	
Gain/(loss) on sale of marketable securities (Note 33.a.1)	(600)	(1,350)	
	5,385,607	16,015,459	
30a.1 Income on sale of marketable securities			
Charge on portfolio	(600)	(1,350)	
	(600)	(1,350)	

SL No.	Particulars	Amount in BDT	
		July 2025 to March 2026	July 2024 to March 2025
31. Current tax			
Profit before tax		(31,800,182)	171,387,499
Add: Accounting depreciation		416,544,599	432,461,581
Less: Tax depreciation		(630,186,441)	(686,085,627)
Rights og Use Assets		(17,881,747)	(17,559,231)
Taxable income		<u>(263,323,771)</u>	<u>(99,795,778)</u>

Income tax provision

Particulars	Taxable Income	Taxable Amount	
		31-Mar-26	31-Mar-25
Income tax on taxable profit	(261,467,701)	-	(23,534,310)
Income tax on export net profit	(2,127,155)	-	1,163,839
Cash Incentive	-	-	361,600
Income tax on dividend received	271,085	54,217	524,275
Total	(263,323,771)	54,217	(21,484,595)

Income Tax

Current Tax (Expenses)/Income	(13,720,001)	(15,302,738)
Deferred Tax (Expenses)/Income	(51,366,932)	(65,337,625)
	<u>(65,086,933)</u>	<u>(80,640,364)</u>

Minimum Tax

Calculation of gross receipt

Revenue from net sales	2,281,280,618	2,534,439,608
Interest on FDR	4,017,040	5,002,624
Dividend income	271,085	2,621,375
Others income	1,098,083	4,776,809
Cash Incentive	-	3,616,000
Total Gross Receipts	2,286,666,825	2,550,456,416

Minimum Tax (.60% On Total Gross Receipts as per sec.163 (5) ka)	<u>13,720,001</u>	<u>15,302,738</u>
--	-------------------	-------------------

Minimum Tax (As per sec.163 (2) kha)	<u>3,168,656</u>	<u>-</u>
--------------------------------------	------------------	----------

Tax provision whichever is higher	<u>13,720,001</u>	<u>15,302,738</u>
-----------------------------------	-------------------	-------------------

Income tax provision is higher between tax at regular rate on income and minimum tax on gross receipts U/S 163 of ITA 2023. Hence tax at regular rate is accounted for as it is higher than the minimum tax.

32 Earnings per share (EPS)

The computation is given below:

Net profit after tax	(221,394,386)	(41,371,610)
Ordinary shares outstanding during the period	234,000,000	234,000,000
Earning per share	<u>(0.95)</u>	<u>(0.18)</u>

Consolidated EPS has been decreased to (.95) rather than (.18) due to decrease of sales as well as no power supply of subsidiaries during the period from previous period.

32a Earnings per share

The computation is given below:

Net profit after tax	(90,596,516)	96,949,135
Ordinary shares outstanding during the period	234,000,000	234,000,000
Earnings per share	<u>(0.39)</u>	<u>0.41</u>

SL No.	Particulars	Amount in BDT	
		July 2025 to March 2026	July 2024 to March 2025
33.	Net Assets Value (NAV) Per Share		
	Total Assets	57,143,737,312	55,796,148,480
	Total Liabilities	37,145,788,134	35,650,312,733
	Net Assets	19,997,949,178	20,145,835,747
	No of shares	234,000,000	234,000,000
	Net Assets Value (NAV) Per Share	85.46	86.09
33a	Net Assets Value (NAV) Per Share		
	Total Assets	42,140,907,715	40,739,239,096
	Total Liabilities	28,687,548,542	27,268,791,224
	Net Assets	13,453,359,173	13,470,447,872
	No of shares	234,000,000	234,000,000
	Net Assets Value (NAV) Per Share	57.49	57.57
34.	Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81 Dated: 20 June 2018:		
	Reconciliation of Net operating cash flow under Indirect Method:		
	Net profit before tax	(201,090,480)	(18,845,649)
	Workers profit participation fund	-	8,569,375
	Interest & other income	(5,385,607)	(16,015,459)
	Financial expenses	216,354,810	235,507,569
	Depreciation	425,568,793	483,929,662
	Increase/(Decrease) in inventory	427,749,408	58,764,923
	Increase/(Decrease) in receivables	(28,594,634)	(330,713,546)
	Increase/(Decrease) in advance deposit & prepayments	(29,628,978)	150,182,836
	Increase/(Decrease) in payable	66,900,429	667,301,356
	Increase/(Decrease) in accrued expenses	110,714,643	32,326,494
	Income taxes paid	(31,445,391)	(37,529,764)
	Net cash flow from operating Activities	951,142,993	1,233,477,797
34.1	Net operating cash flow per share	4.06	5.27
	NOCFPS decreased to 4.06 than 5.27 of the previous corresponding period. During the period cash received from customer is decreased than the previous corresponding period.		
34.a	Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81 Dated: 20 June 2018:		
	Reconciliation of Net operating cash flow under Indirect Method:		
	Net profit before tax	(31,800,182)	171,387,499
	Workers profit participation fund	-	8,569,375
	Interest & other income	(5,385,607)	(16,015,459)
	Financial expenses	198,055,191	159,731,686
	Depreciation	416,544,599	432,461,581
	Increase/(Decrease) in inventory	64,207,506	(34,477,143)
	Increase/(Decrease) in receivables	17,263,138	67,877,070
	Increase/(Decrease) in advance deposit & prepayments	(33,491,117)	169,053,018
	Increase/(Decrease) in payable	(9,529,219)	41,317,009
	Increase/(Decrease) in accrued expenses	1,308,613	5,847,700
	Income taxes paid	(31,445,391)	(37,529,764)
	Net cash flow from operating activities	585,727,531	968,222,572
34a.1	Net operating cash flow per share	2.50	4.14

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

Sd/-
Director

Sd/-
Managing Director

Sd/-
Chairman